Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TET2 | Q6N021 | 1/20 | 1.00 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.67 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 5/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | MGAM | O43451 | 1/20 | 0.40 |
| ▸ | SI | P14410 | 1/20 | 0.40 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2760574 | 0.84 | — | — | |
| SCHEMBL22314666 | 0.82 | TET2 (0.69) | TET2EGLN1RECQLGAATGFBR1 | |
| SCHEMBL18039340 | 0.82 | TET2 (0.69) | TET2EGLN1TSHRGAAKDM4E | |
| SCHEMBL1809100 | 0.82 | TET2 (0.69) | TET2EGLN1RECQLTSHRHSD17B10 | |
| SCHEMBL2138187 | 0.80 | EGLN1 (0.67) | TET2EGLN1RECQLTSHRGAA | |
| SCHEMBL18039446 | 0.80 | TET2 (0.67) | TET2EGLN1RECQLTSHRHSD17B10 | |
| SCHEMBL16133035 | 0.80 | EGLN1 (1.00) | TET2EGLN1TSHRKDM4ETGFBR1 | |
| SCHEMBL13686153 | 0.80 | TET2 (0.67) | TET2EGLN1RECQLTSHRHSD17B10 | |
| SCHEMBL29883431 | 0.79 | TET2 (0.62) | TET2EGLN1RECQLTSHRHSD17B10 | |
| SCHEMBL13684762 | 0.76 | TET2 (0.61) | TET2EGLN1RECQLTSHRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 575 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107052-A1 | COMBINATION TREATMENTS USING EPIGENETIC INHIBITION AND SYNGRI-MEDIATED FRATAXIN EXPRESSION | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. (US) | 2026-05-21 | — | — | WO | claimed |
| US-20260124274-A1 | METHODS OF INCREASING READTHROUGH OF A PREMATURE TERMINATION CODON | UNIV RAMOT (IL) | 2026-05-07 | — | — | US | claimed |
| EP-4712948-A2 | GENE EDITING SYSTEMS AND COMPOSITIONS FOR TREATMENT OF HEMOGLOBINOPATHIES AND METHODS OF USING THE SAME | Renagade Therapeutics Management Inc. (US) | 2026-03-25 | — | — | EP | claimed |
| EP-3947736-B1 | PROGNOSIS METHOD OF CANCER | CENTRE NAT RECH SCIENT (FR) | 2026-03-11 | — | — | EP | claimed |
| US-20260027096-A1 | PHD INHIBITORS | UNIV OXFORD INNOVATION LTD (GB) | 2026-01-29 | — | — | US | claimed |
| EP-3803568-B1 | AGGREGATION OF CONNECTED OBJECTS | ORANGE (FR) | 2026-01-28 | — | — | EP | claimed |
| EP-4680243-A1 | METHODS FOR TREATMENT OF AGE-RELATED MACULAR DEGENERATION | The United States of America, as represented by the Secretary, Department of Health and Human Services (US) | 2026-01-21 | — | — | EP | claimed |
| EP-4661861-A1 | USE OF HIF-1A STABILIZING AGENTS FOR THE TREATMENT OF TYPE I INTERFERONOPATHIES | Institut National de la Santé et de la Recherche Médicale (FR) | 2025-12-17 | — | — | EP | claimed |
| EP-4655288-A1 | PHD INHIBITORS | Oxford University Innovation Limited (GB) | 2025-12-03 | — | — | EP | claimed |
| WO-2025049959-A9 | GENE EDITING SYSTEMS, COMPOSITIONS, AND METHODS FOR TREATMENT OF VEXAS SYNDROME | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2025-06-12 | — | — | WO | claimed |
| US-20220347167-A1 | A NEW TREATMENT FOR MEIBOMIAN GLAND DYSFUNCTION | THE SCHEPENS EYE RESEARCH INSTITUTE, INC. | 2022-11-03 | — | — | US | claimed |
| WO-2022132678-A1 | BIOLOGICAL DELIVERY SYSTEMS | DNALITE THERAPEUTICS, INC. (US) | 2022-06-23 | — | — | WO | claimed |
| US-20220186321-A1 | PROGNOSIS METHOD OF CANCER | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2022-06-16 | — | — | US | claimed |
| US-11311538-B2 | Compositions and methods for targeting cancers | YALE UNIVERSITY (US) | 2022-04-26 | — | — | US | claimed |
| EP-3947736-A1 | PROGNOSIS METHOD OF CANCER | Centre national de la recherche scientifique (FR) | 2022-02-09 | — | — | EP | claimed |
| US-20200397777-A1 | PREVENTION AND TREATMENT OF ORGAN FIBROSIS | CORNELL UNIVERSITY | 2020-12-24 | — | — | US | claimed |
| EP-3737693-A2 | PREVENTION AND TREATMENT OF ORGAN FIBROSIS | Cornell University (US) | 2020-11-18 | — | — | EP | claimed |
| CN-111819190-A | Prevention and treatment of organ fibrosis | 康奈尔大学 | 2020-10-23 | — | — | CN | claimed |
| US-20190298709-A1 | HIF-STABILIZATION AND PREVENTION OF HYPEROXIA-INDUCED NEONATAL LUNG DISEASE | CORNELL UNIVERSITY | 2019-10-03 | — | — | US | claimed |
| WO-2017143131-A1 | HIF-STABILIZATION AND PREVENTION OF HYPEROXIA-INDUCED NEONATAL LUNG DISEASE | CORNELL UNIVERSITY (US) | 2017-08-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220347167-A1 | A NEW TREATMENT FOR MEIBOMIAN GLAND DYSFUNCTION | HIF1AN, HIF1A, MTNR1A | TET2 2294/4885EGLN1 11/4885RECQL 1614/4885 |
| US-20260124274-A1 | METHODS OF INCREASING READTHROUGH OF A PREMATURE TERMINATION CODON | RNMT, TRMT1L, UPF1 | TET2 1402/4885EGLN1 3552/4885RECQL 1747/4885 |
| US-20260027096-A1 | PHD INHIBITORS | HIF1AN, HIF1A, EGLN1 | TET2 34/4885EGLN1 3/4885RECQL 4147/4885 |
| US-20190298709-A1 | HIF-STABILIZATION AND PREVENTION OF HYPEROXIA-INDUCED NEONATAL LUNG DISEASE | HIF1AN, HIF1A, EGLN2 | TET2 3136/4885EGLN1 5/4885RECQL 3598/4885 |
| US-20200397777-A1 | PREVENTION AND TREATMENT OF ORGAN FIBROSIS | MMP1, P4HA1, SERPINH1 | TET2 4313/4885EGLN1 1390/4885RECQL 830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.